BRL-15,572
| BRL-15,572 | |
|---|---|
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | 127464-43-1 |
| PubChem | 65880 |
| DrugBank | |
| ChemSpider | 59288 |
| KEGG | |
BRL-15,572 is an experimental antidepressant drug that acts as a selective 5-HT1A receptor partial agonist. It was developed by GlaxoSmithKline in the 1990s. The compound has been studied for its potential to treat depression and anxiety disorders.
Pharmacology[edit]
BRL-15,572 functions primarily as a selective 5-HT1A receptor partial agonist. The 5-HT1A receptor is a subtype of the serotonin receptor that is implicated in the regulation of mood and anxiety. By modulating the activity of this receptor, BRL-15,572 may help to alleviate symptoms of depression and anxiety.
Research[edit]
Preclinical studies have shown that BRL-15,572 has potential antidepressant and anxiolytic effects. However, its development has not progressed to clinical trials, and it remains an experimental compound. Further research is needed to fully understand its efficacy and safety profile.
See also[edit]
References[edit]
 | This medical article is a stub. You can help WikiMD by expanding the page. |
